2.094 hasil
Menampilkan 1–20 · 1,02 detik · RSS
OncoImmunology
Scopus
ISSN 2162-402X · Taylor & Francis Group · 2.094 artikel di indeks
-
Artikel Jurnal
The double face of IL-1β in lung cancer
Interleukin (IL)-1β is known to promote lung cancer growth in both humans and mice. However, in the context of the current standard of care, which includes chemotherapy and immune checkpoint inhibitors, IL-1β can overcome resistance.
-
Artikel Jurnal
Single-cell landscape of peripheral and tumor-infiltrating immune cells in HPV-negative HNSCC
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. HPV-negative HNSCC, arising in diverse upper airway mucosal niches, is particularly aggressive, with poor 5-y survival and a limited response to immune checkpoint inhibitors. A deeper understanding of the…
-
Artikel Jurnal
Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models
Steroid receptor coactivator 3 (SRC-3) is highly expressed in regulatory T cells (Tregs) and is important for their immunosuppressive activity. Recently, we demonstrated that disrupting SRC-3 expression in Tregs eliminates triple-negative breast cancer (TNBC) and prostate cancer in syngeneic animal…
-
Artikel Jurnal
Contrasting functions of CD73 and adenosine in CD8+ T-cell exhaustion during antitumor immunity
T-cell exhaustion is a state of functional decline in T cells, driven by chronic antigen exposure and inhibitory signals within the tumor microenvironment. Exhausted CD8+ T cells (Tex) derive from precursor exhausted T cells (Tpex), a self-renewing population responsible for the proliferative burst…
-
Artikel Jurnal
PD-1 genetic fate mapping uncovers immune cell diversity mediating the efficacy of combined PD-1 blockade and chemotherapy
Combined cytotoxic chemotherapy and immune checkpoint inhibition (ICI) improves outcomes in PD-L1–low lung cancer, but transient and broad PD-1 expression across immune cells complicates the understanding of the underlying mechanisms. We generated Pdcd1-CreERT2 fate-mapping mice to trace…
-
Artikel Jurnal
B cells and humoral immunity in melanoma: regulatory and autoimmune-like features and implications for immunotherapy
B cells and the humoral immune response are increasingly recognized as critical modulators of melanoma progression and immunotherapy outcomes. While checkpoint inhibitor (CPI) therapy was developed to target T cell exhaustion mechanisms, emerging evidence highlights the complexity and clinical…
-
Artikel Jurnal
Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanoma
Immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced melanoma, yet their efficacy is limited by high-grade immune-related adverse events that often require treatment with systemic corticosteroids. Although corticosteroids are widely used, their impact on anti-tumor…
-
Artikel Jurnal
Multidimensional immune profiling uncovers biphasic peripheral T-cell dynamics after chemoradiation in patients with locally advanced head and neck cancer
Cisplatin-based concurrent chemoradiation (CRT) remains the standard treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC), yet recurrence rates remain high. Attempts to combine immune checkpoint inhibitors with CRT have not improved outcomes, underscoring the need to…
-
Artikel Jurnal
Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics
Over the past decades, cancer immunotherapy has evolved into clinical practice, with bispecific T cell engagers (TCEs) and other higher-order multispecific immunotherapeutics emerging as approaches for precision immune modulation. These engineered antibodies redirect immune effector cells toward…
-
Artikel Jurnal
Monocytes acquire a tumor-associated IL1B program upon encountering patient-derived colon cancer organoids
Tumor-associated macrophages (TAMs) and monocytes that accumulate in colorectal cancer (CRC) play a crucial role in shaping the tumor microenvironment (TME) and anti-tumor immune responses. Although TAMs have been linked to both pro- and anti-tumor functions, our understanding of the cues…
-
Artikel Jurnal
TNF-α deficiency underlies NK cell dysfunction in colorectal cancer
Natural killer (NK) cells are central to innate antitumor immunity, yet their function is systemically compromised in colorectal cancer (CRC). We show that CRC patients exhibit early and pronounced alterations in peripheral blood NK cells, marked by a reduced frequency of total CD56⁺ cells, a shift…
-
Artikel Jurnal
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma
Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial…
-
Artikel Jurnal
Serum Arginase−1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness
While recent advances in immuno-oncology have revolutionized cancer therapy, only a subset patients benefit from these treatments and achieve durable clinical responses. Biomarker-guided identification of patients likely to respond to immunotherapy could enable more effective management of various…
-
Artikel Jurnal
KRAS-elicited PDIA6 blocks PERK-dependent immunogenic cell death in pancreatic carcinoma
KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) remains largely refractory to immune checkpoint blockade. Wang et al. identified PDIA6 as a KRAS-driven suppressor of PERK-dependent immunogenic cell death, fostering immune exclusion. PDIA6 inhibition restores CD8+ T-cell immunity and sensitizes…
-
Artikel Jurnal
Modular mRNA cocktail enables synergistic activation of antigen-specific T cells for cancer immunotherapy
mRNA-based therapeutics have demonstrated notable success in SARS-CoV-2 vaccines and are emerging in cancer immunotherapy. However, conventional mRNA cancer vaccines are limited in part by the low immunogenicity of tumor-associated and neoantigens. We addressed this limitation by formulating a…
-
Artikel Jurnal
IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy
Durable antitumor immunity requires innate activation, antigen presentation, lymphocyte priming, trafficking, and effector function. In immunologically cold tumors, deficient dendritic-cell and natural killer (NK)-cell activation limits the transition from tumor-antigen recognition to CD8 T-cell…
-
Artikel Jurnal
Circadian timing of first-line chemoimmunotherapy is associated with survival in extensive-stage small cell lung cancer
Growing evidence suggests that circadian timing influences the efficacy of immune checkpoint inhibitors across multiple malignancies. However, evidence in extensive-stage small cell lung cancer (ES-SCLC) remains limited to a single East Asian cohort, and independent validation in other populations…
-
Artikel Jurnal
Clinical outcomes and blood-based biomarkers across two SABR-treated metastatic settings: oligoprogression under immune checkpoint inhibition and oligometastatic disease
Stereotactic ablative radiotherapy (SABR) may extend the clinical benefit of immune checkpoint inhibitors (ICI) in patients with oligoprogressive disease. However, individual benefit varies, and validated biomarkers to guide patient selection are lacking. We hypothesize that cell-free DNA (cfDNA)…
Menampilkan maksimal 50 halaman. Persempit pencarian dengan filter untuk hasil yang lebih spesifik.